Literature DB >> 6283229

Renal hemodynamics and renal kinins after angiotensin-converting enzyme inhibition.

B H Clappison, W P Anderson, C I Johnston.   

Abstract

The effect of the angiotensin-converting enzyme (ACE) inhibitor captopril on the renal kallikrein-kinin system and renal hemodynamics was studied in anesthetised dogs for 45 min after captopril administration. ACE inhibition was confirmed by increases in blood angiotensin I (AI) and plasma renin activity and a 20-fold decrease in sensitivity of the blood pressure and renal blood flow dose-response curves to AI. Captopril (1.5 mg . kg-1, i.v.) led to an increase in renal blood flow of 56 +/- 13 ml/min-1 (P less than .01) despite a fall in mean arterial pressure of 17 +/- 5 mm Hg (P less than 0.005). Glomerular filtration rate did not change whereas the filtration fraction decreased (p less than 0.005). The hypotension and renal vasodilation were accompanied by an increase in urinary kinin excretion (P less than .025) but no acute change in circulating kinins or urinary kallikrein excretion. Urine volume and urinary sodium and potassium excretion increased. To determine the contribution of the renin-angiotensin system to these hemodynamic changes, were gave captopril to a further group of dogs during a continuous infusion of the competitive angiotensin II (AII) receptor antagonist sar1ile8-AII (2.5 micrograms/kg/min). Subsequent ACE inhibition was still associated with an increase in renal blood flow of 35 +/- 17 ml/min-1 (P less than 0.05), decrease with a mean arterial pressure by 11 +/- 4 mm Hg (P less than 0.025). These results suggest that ACE inhibition increases levels of intra-renal kinins and that decreased degradation of these tissue vasodilator peptides may contribute significantly to the acute renal vasodilation and hypotensive effect of captopril.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6283229     DOI: 10.1038/ki.1981.184

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  9 in total

Review 1.  Circulating and tissue angiotensin systems.

Authors:  D J Campbell
Journal:  J Clin Invest       Date:  1987-01       Impact factor: 14.808

2.  Effects of fosinopril on renal function, baroreflex response and noradrenaline pressor response in conscious normotensive dogs.

Authors:  C Buranakarl; A Kijtawornrat; P Nampimoon
Journal:  Vet Res Commun       Date:  2001-07       Impact factor: 2.459

3.  Captopril augments both basal and frusemide-induced natriuresis in normal man by suppression of circulating angiotensin II.

Authors:  J G Motwani; A D Struthers
Journal:  Br J Clin Pharmacol       Date:  1992-07       Impact factor: 4.335

4.  Frusemide, ACE inhibition, renal dopamine and prostaglandins: acute interactions in normal man.

Authors:  T M MacDonald; K Craig; M L Watson
Journal:  Br J Clin Pharmacol       Date:  1989-12       Impact factor: 4.335

5.  Long-term effects of captopril on renal function in hypertensive patients.

Authors:  Z Glück; C Beretta-Piccoli; F C Reubi
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

6.  The role of endogenous angiotensin II in the regulation of renal haemodynamics and proximal fluid reabsorption in the rat.

Authors:  J Zhuo; D Thomas; P J Harris; S L Skinner
Journal:  J Physiol       Date:  1992       Impact factor: 5.182

7.  [Angiotensin-converting enzyme inhibition: direct and indirect mechanisms].

Authors:  K O Stumpe
Journal:  Klin Wochenschr       Date:  1985-09-16

8.  Reversal by angiotensins II and III of the effects of converting enzyme inhibition on renal electrolyte excretion in rats.

Authors:  P J Harris; J O Munro
Journal:  J Physiol       Date:  1984-06       Impact factor: 5.182

9.  Metabolically stable bradykinin B2 receptor agonists enhance transvascular drug delivery into malignant brain tumors by increasing drug half-life.

Authors:  Hemant Sarin; Ariel S Kanevsky; Steve H Fung; John A Butman; Robert W Cox; Daniel Glen; Richard Reynolds; Sungyoung Auh
Journal:  J Transl Med       Date:  2009-05-13       Impact factor: 5.531

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.